Timothy A Yap MD

Clinical Trials

• IACS-010759 in Advanced Cancers Start of enrollment: 2017 Nov 13

  Completed

  Phase 1

• Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations Start of enrollment: 2019 Nov 21

  ACTIVE_NOT_RECRUITING

  PHASE1

• Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study Start of enrollment: 2020 Jun 30

  ACTIVE_NOT_RECRUITING

  PHASE1

• Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors Start of enrollment: 2020 Mar 17

  ACTIVE_NOT_RECRUITING

  PHASE1, PHASE2

• Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN Start of enrollment: 2020 Jul 17

  ACTIVE_NOT_RECRUITING

  PHASE1, PHASE2

• Study of RP-3500, Camonsertib, in Advanced Solid Tumors Start of enrollment: 2020 Jul 22

  ACTIVE_NOT_RECRUITING

  PHASE1, PHASE2

• Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Start of enrollment: 2020 Sep 28

  Terminated

  Phase 1

• Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies Start of enrollment: 2020 Nov 12

  RECRUITING

  PHASE1, PHASE2

• Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial Start of enrollment: 2020 Dec 01

  RECRUITING

  PHASE1

• SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIAL Start of enrollment: 2021 Feb 09

  Terminated

  Phase 1

• IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors Start of enrollment: 2021 Sep 09

  RECRUITING

  PHASE1

• Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations Start of enrollment: 2022 Sep 27

  ACTIVE_NOT_RECRUITING

  PHASE2

  Roles: Principal Investigator, Contact

• Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301) Start of enrollment: 2019 Dec 20

  ACTIVE_NOT_RECRUITING

  PHASE1

  Roles: Principal Investigator

• Phase 1 Study of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors Start of enrollment: 2019 Aug 01

  Recruiting

  Phase 1

  Roles: Principal Investigator, Contact

• Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers Start of enrollment: 2024 Jan 30

  RECRUITING

  PHASE1

  Roles: Contact, Principal Investigator

• Join now to see all